Cyteir Therapeutics

Scroll
Investment area
Novo Ventures
Region
Eastern USA
Date of investment
August 2019
Website
http://cyteir.com/

Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).